COPD Coalition
COPD Coalition
US COPD Coalition
  • Menu
  • Home
  • About Us
  • Members & Board
  • Caucus & Advocacy
  • State Coalitions
  • Resources & News
    • Resources
    • News And Events
    • Resource Forum
  • Corporate Supporters
  • Site Search
News and Events
25 Latest Articles Current Articles | Archives | Search
18

FDA Warns of Stolen Advair Diskus Use

Admin posted on July 18, 2010

The FDA issued an important warning for Advair users on Friday, alerting them to the potential for stolen inhalers to appear in some pharmacies. Since the safety of the stolen inhalers cant be guaranteed it is important to read the full release and make sure the lot numbers of your inhalers do not match the numbers that FDA has posted. There are detailed instructions on what to do if you discover your lot numbers do match the FDA list.

FDA NEWS RELEASE

For Immediate Release: July 16, 2010

Media Inquiries: Elaine Gansz Bobo, 301-796-7567, Elaine.Bobo@fda.hhs.gov

Consumer Inquiries: 888-INFO-FDA

The FDA is warning the public that certain Advair Diskus inhalers stolen from a distribution warehouse in 2009 have been found in some pharmacies. The safety and effectiveness of the stolen inhalers cannot be assured and they should not be used.

Advair Diskus (fluticasone propionate and salmeterol inhalation powder) is an inhalerused to treat patients with asthma and chronic obstructive pulmonary disease.

The products were reported stolen in August 2009 from a GlaxoSmithKline warehouse near Richmond, Va. The inhalers found recently were the first from the stolen lots to be found in commerce. However, more stolen product may still be on the market and the FDA continues to aggressively investigate the matter.

Stolen medicine may be harmful because it may have been stored at the wrong temperature or humidity or other improper conditions, may degrade or lose potency, become contaminated, or may have been tampered with or handled improperly while outside of the legitimate supply chain.

The lot numbers, doses, and quantities of the stolen Advair Diskus inhalers are:

Lot 9ZP2255 – NDC 0173-0696-00, Advair Diskus 250/50, 60 Dose, Exp: Sep 2010 (14,400 inhalers)

Lot 9ZP3325 – NDC 0173-0697-00, Advair Diskus 500/50, 60 Dose, Exp: Sep 2010 (11,200 inhalers)

Patients who have products with these lot numbers should immediately stop using them, contact GlaxoSmithKline’s Customer Response Center at 888-825-5249, and follow-up with their physician or pharmacist to obtain a proper replacement.

Pharmacists and wholesalers who find Advair Diskus inhalers bearing these lot numbers should remove them from shelves and contact the FDA’s Office of Criminal Investigations (OCI) at 800-551-3989. The agency also is asking for the public’s help in reporting any information regarding these inhalers, including suspicious or unsolicited offers for the Advair Diskus lots in question, to OCI or by visiting the OCI website.

The FDA invites pharmacists and wholesalers to visit the FDA’s Cargo Theft Web page to check their inventory for other stolen products. The FDA is committed to protecting American consumers from the threat of stolen, counterfeit, and diverted FDA-regulated products such as prescription or over-the-counter medicines, medical devices, or infant formula.

Read the original release here.

 

Navigation

  • Resources
  • News And Events
  • Resource Forum

Archives

February 2019 (2)
January 2019 (3)
December 2018 (1)
November 2018 (8)
October 2018 (3)
September 2018 (2)
August 2018 (6)
July 2018 (3)
June 2018 (4)
May 2018 (3)
April 2018 (2)
March 2018 (1)
February 2018 (2)
January 2018 (7)
December 2017 (2)
November 2017 (3)
October 2017 (3)
September 2017 (3)
August 2017 (3)
July 2017 (4)
April 2017 (3)
March 2017 (8)
February 2017 (2)
December 2016 (2)
November 2016 (2)
October 2016 (2)
September 2016 (4)
August 2016 (1)
July 2016 (1)
June 2016 (4)
January 2016 (1)
November 2015 (3)
October 2015 (2)
August 2015 (1)
November 2014 (1)
October 2014 (2)
July 2014 (2)
June 2014 (1)
April 2014 (1)
March 2014 (4)
July 2013 (1)
January 2013 (2)
October 2012 (1)
September 2012 (1)
August 2012 (2)
July 2012 (2)
June 2012 (2)
May 2012 (2)
March 2012 (2)
December 2011 (1)
November 2011 (1)
October 2011 (2)
September 2011 (1)
August 2011 (2)
July 2011 (2)
June 2011 (1)
April 2011 (2)
March 2011 (1)
February 2011 (1)
January 2011 (1)
December 2010 (3)
November 2010 (1)
October 2010 (1)
August 2010 (1)
July 2010 (3)
June 2010 (1)

Latest

Alpha-1 Foundation Names Miriam O'Day President & CEO
Sterile Water and Saline for Inhalation Recalled
DHHS Publishes Policy Brief on COPD in Rural America
HHS Secretary Azar Takes on Medicare Part B Drug Costs
Rural Health Policy Institute Conference To Be Held February 5 - 7, 2019
CDC Reports that Flu Season Has Arrived
NIH Statement on World COPD Day 2018
Webinar to Focus on the Impact of Commercial Tobacco on Tribal Communities
Protection Against Wildfire Smoke Requires Special Type of Face Mask
Learn About the Symptoms, Diagnosis and Treatment of COPD
Take the Kids4COPD Challenge
FDA to Ban Most Flavored E-Cigarettes In Effort To Reduce Youth Nicotine Addiction
FDA Approves New COPD Maintenance Drug
November 2018 USCC Member Meeting & Webinar Available for Viewing
COPD Pocket Consultant Guide (PCG) App for Healthcare Providers is Here!
FDA Approves New Influenza Drug
NIH Study Finds Probiotic Bacillus Effective Against Staphylococcus Bacteria
USCC Joins Other Advocacy Groups in Letter to CMS
Congressman Chris Stewart to Co-Chair Congressional COPD Caucus
CPAP Mask Cushion Recalled Due to Possible Air Leaks
Second-Hand Smoke Exposure as Child Raises Risk of Death from COPD as Adult
Generic EpiPen Approved by FDA
FDA Launches New Medication Guide Database
ALA Reports Coordinated Attack on Medicaid that Threatens Access to Care
CMS Seeking Public Comments on Proposed Rule Changes for Oxygen Reimbursement
Study Finds Vaping May Not Help Smokers Quit
FDA Warns Consumers of New Scam
FDA Approves New Breathing Valve for Severe Emphysema
Cigar Smoking Just as Unhealthy as Cigarettes
USCC Board of Directors Election Results Announced
Join Us for the USCC Virtual Member Meeting & Webinar
NHLBI is Turning 70, and You Are Invited to Join the Celebration!
Respiratory Therapists Lobby for Pilot COPD Telehealth Program
COPD and Rural Health Resources Now Available
U.S. COPD Coalition Board of Directors Ballot
Ask Your Members of Congress to Join the Congressional COPD Caucus
FDA Cracks Down on Youth Access to Juul and Other e-Cigarettes
COPD in Rural America Topic of Congressional Briefing
CDC Report Suggests Burden of COPD Greater in Rural Areas
Join Us for the USCC Virtual Member Meeting & Webinar
Vyaire Medical Recalls AirLife Humidification Chamber & Heated Breathing Circuit Kits Due to Manufacturing Error
New Report Released on Health Effects of e-Cigarettes
NIH Seeking Participants for Asthma Research Study
National Institutes of Health Seeks Your Input for Research Priorities
U.S. COPD Coalition Board Members Lend Patient Perspective to Peer Reviewed Medical Research Program
Researchers Discover Potential Genetic Indicators For COPD Risk
Study Reveals that Adequate Evaluation for Supplemental Oxygen Rarely Occurs in Hospitalized COPD Patients
FDA Lifts Black Box Warning from Combination Long-Acting Bronchodilator/Corticosteroid Inhalers
Long-acting Nebulized Medication Receives FDA Approval
Federal Court Orders Big Tobacco To Issue "Corrective Statements" on Tobacco
US COPD Coalition

The U.S. COPD Coalition
1140 3rd St NE, 2nd Floor
Washington, DC 20002
ksiegel@uscopdcoalition.org

The U.S. COPD Coalition wants to collaborate with all groups that want to take action on COPD in the United States.  

Please feel free to contact us.

 

Copyright 2019 by US Copd Coalition Disclaimer| Privacy| Login | Contact Us Site Credits